According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.
Read Press ReleaseAmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenvironment.
Read Press ReleaseNew multiyear collaboration between Florence Healthcare and IQVIA to ensure research sites participating in IQVIA studies have access to best-in-class site enablement technology to streamline operations and power remote connectivity.
Read Press ReleaseNTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion. NTM-001 has the Potential to Deliver Opioid-Level Pain Relief Without Analgesic Gaps and Reduce or Eliminate the Need for Opioids. Phase 3 Efficacy and Safety Study is Comparing NTM-001 vs. Placebo, and Includes a Morphine Arm for Assay Sensitivity in Patients with Moderately Severe Pain After Bunionectomy Surgery. Results Expected Second Half 2023.
Read Press ReleasePresentation to include clinical data from a phase 2 study of Gruticibart (AB023), a factor XI-targeted antibody being developed for the treatment and prevention of thrombosis and inflammation
Read Press Release